Evinova Partners with Quantum Leap to Integrate RPM into Breast Cancer Trial

Evinova's RPM technology continuously tracks patients' health status and medication adherence between clinical visits.

Evinova, a global leader in clinical trial technology, has partnered with Quantum Leap Healthcare Collaborative (QLHC) to incorporate its remote patient monitoring (RPM) solution into the ongoing I-SPY 2.2 clinical trial.

I-SPY 2.2 is the largest and longest-running platform trial that evaluates multiple innovative therapeutic treatments for women with newly diagnosed, locally advanced breast cancer.

Evinova's RPM solution will be deployed to monitor early symptoms of interstitial lung disease (ILD), a potential adverse event linked to one of the novel treatments being studied.

This technology aims to enhance patient safety and improve clinical outcomes by providing real-time symptom alerts.

Dr Laura Esserman, founder of the I-SPY trials and QLHC, emphasized the importance of early detection in reducing treatment-related side effects.

"One of the primary goals of I-SPY 2.2 is to identify better treatment options that are both more effective and less toxic. While new therapies, such as bispecific antibodies and antibody-drug conjugates, hold promise in reducing the reliance on traditional chemotherapy, they still carry risks, including ILD," she stated.

Using Evinova's RPM solution, providers can monitor patients daily from their homes and intervene at the earliest signs of ILD symptoms, potentially preventing the condition from escalating.

"This solution allows us to study how remote monitoring can enhance patient experience while minimizing toxicity, which is crucial to improving cancer care," Esserman added.

Real-Time Monitoring for Proactive Clinical Decisions

Evinova's RPM technology continuously tracks patients' health status and medication adherence between clinical visits. It alerts healthcare teams immediately when potential toxicity symptoms arise, enabling swift clinical assessments.

This early intervention approach may help reduce severe cases of ILD, minimizing the need for dose reductions or treatment interruptions.

"With real-time alerts to both patients and healthcare sites, our RPM solution ensures that care teams can make proactive clinical decisions based on established guidelines," said Cristina Duran, President of Evinova.

She highlighted that technology-driven monitoring tools like RPM help life science leaders overcome critical research challenges, ultimately enhancing the clinical trial experience for patients and investigators alike.

Beyond pulmonary toxicity, Evinova's RPM technology also includes modules for monitoring gastrointestinal issues, stomatitis, and oral thrush. Additional developments are underway based on patient needs and drug side effect profiles.

Stay tuned for more such updates on Digital Health News.